Showing 5391-5400 of 5643 results for "".
- GenSight Biologics Reports Sustained Quality of Life Improvements at Week 72 of Phase 3 REVERSE Clinical Trialhttps://modernod.com/news/gensight-biologics-reports-sustained-quality-of-life-improvements-at-week-72-of-phase-3-reverse-clinical-trial/2479619/GenSight Biologics reported that week 72 analyses of the data from its phase 3 REVERSE clinical trial revealed a sustained improvement in composite scores and selected sub-scores of a questionnaire used to measure patient perceptions of vision-related quality of life and ability to carry out dail
- SECO International Partners With the American Society of Optometric Surgeons for SECO 2019https://modernod.com/news/seco-international-partners-with-the-american-society-of-optometric-surgeons-for-seco-2019/2479621/SECO International has announced that SECO, the educational conference providing ophthalmic professionals educational opportunities since 1924, has partnered with the American Society of Optometric Surgeons (ASOS) to bring hands-on demonstrations showing radiosurgical technology, Botox, and YAG l
- Wills Eye Hospital’s Training in Ophthalmology Voted #1 Top Eye Residency Program in Nationhttps://modernod.com/news/wills-eye-hospitals-training-in-ophthalmology-voted-1-top-eye-residency-program-in-nation/2479623/The Wills Eye at Jefferson Residency Program in Philadelphia has been voted the #1 medical education training program in ophthalmology in the nation, according to Doximity.com. The Wills Eye Hospital faculty serve as the department of Ophthalmology at Thomas Jefferson
- Criminal Case Against James Mazzo Dismissedhttps://modernod.com/news/criminal-case-against-james-mazzo-dismissed/2476151/After a legal battle that spanned a decade, the insider trading criminal case against ophthalmic executive James Mazzo has come to an end. Late Thursday at the Ronald Reagan Federal Building in Santa Ana, California, federal prosecutors asked Judge Andrew Guilford to dismiss all criminal c
- Center for Vision and Population Health at Prevent Blindness Established to Implement Strategies to Address Eye Healthhttps://modernod.com/news/center-for-vision-and-population-health-at-prevent-blindness-established-to-implement-strategies-to-address-eye-health/2476154/Healthy vision can be a key component to independence and well-being for people of all ages. However barriers such as poor access to eye care, lack of insurance coverage, and inconsistent policies for eye health can prevent early detection and treatment of eye disorders. Prevent Blindness,
- Clearside Presents Additional Analyses of PEACHTREE Clinical Trial Data in Support of Xipere in Treating Uveitic Macular Edemahttps://modernod.com/news/clearside-presents-additional-analyses-of-peachtree-clinical-trial-data-in-support-of-xipere-in-treating-uveitic-macular-edema/2476155/Clearside Biomedical recently announced that additional data from PEACHTREE, the company’s pivotal phase 3 trial of Xipere (formerly suprachoroidal CLS-TA) in patients with uveitic macular edema, were presented by Rahul N. Khurana, MD, Vitreoretinal Surgeon at Northern California
- 4D Molecular Therapeutics Announces Collaboration to Advance Gene Therapies for Retinal Diseases with Oregon Health & Sciencehttps://modernod.com/news/4d-molecular-therapeutics-announces-collaboration-to-advance-gene-therapies-for-retinal-diseases-with-oregon-health-science/2476157/4D Molecular Therapeutics (4DMT) announced a research and development collaboration with the Casey Eye Institute and the Oregon National Primate Research Center at Oregon Health & Science University (OHSU). The collaboration will combine the complementary expertise of 4D Molecular Therapeutic
- Spark Therapeutics Gene Therapy Pioneers Win $1 Million Sanford Lorraine Cross Awardhttps://modernod.com/news/spark-therapeutics-gene-therapy-pioneers-win-1-million-sanford-lorraine-cross-award/2476159/Two women with a vision to make the blind see were the winners of the inaugural $1 million Sanford Lorraine Cross Award. Jean Bennett, MD, PhD, and Katherine A. High, MD, whose work with the RPE65 mutation has reversed an inherited form of blindness, accepted the award on December 4 at Sanford He
- Oncobiologics Changes Name to Outlook Therapeutics; Announces Next Steps for ONS-5010 Clinical Strategyhttps://modernod.com/news/oncobiologics-changes-name-to-outlook-therapeutics-announces-next-steps-for-ons-5010-clinical-strategy/2476161/Oncobiologics announced several key corporate events that enhance the company’s ability to advance the development of its lead product candidate, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (AMD). These events are in c
- Takeda Shareholders Back Shire Purchasehttps://modernod.com/news/takeda-shareholders-back-shire-purchase/2479627/Shareholders of Japanese pharmaceutical company Takeda overwhelmingly voted in favor of acquiring UK-based Shire. The deal, currently valued at about $58 billion dollars, makes Takeda a top 10 global drugmaker by sales. Takeda shareholders on Wednesday voted 88 percent in favor in of thee